TABLE 1.
Baseline characteristics of the Sister Study (2003–2009)a
| Full Cohort (N=33,858) | Uterine Cancer Cases (N=274) | |
|---|---|---|
| Age; Mean (std) | 54.2 (8.9) | 58.7 (8.1) |
| Follow-up time; Mean (std) | 8.3 (2.2) | 4.9 (2.8) |
| Age at menarche; Mean (std) | 12.7 (1.5) | 12.5 (1.4) |
| Race; N (%) | ||
| Non-Hispanic White | 28,915 (85) | 243 (89) |
| Non-Hispanic Black | 2,476 (7.3) | 17 (6.2) |
| Hispanic | 1,611 (4.7) | 10 (3.7) |
| Other | 849 (2.5) | 4 (1.5) |
| Education; N (%) | ||
| High school or less | 4,535 (13) | 36 (13) |
| Some college | 10,501 (31) | 87 (32) |
| Bachelor’s degree | 9,910 (29) | 70 (26) |
| Graduate degree | 8,906 (26) | 81 (30) |
| Weight relative to peers, age 10; N (%) | ||
| Lighter | 11,731 (35) | 90 (33) |
| Same weight | 15,776 (47) | 127 (47) |
| Heavier | 6,253 (19) | 54 (20) |
| Body Mass Index (BMI); N (%) | ||
| <25.0 kg/m2 | 14,444 (43) | 75 (27) |
| 25–<30 kg/m2 | 10,351 (31) | 77 (28) |
| 30 kg/m2 | 9,052 (27) | 122 (45) |
| Postmenopausal; N (%) | 19,323 (57) | 202 (74) |
| Hormonal Contraception Use; N (%) | ||
| None | 5,148 (15) | 64 (23) |
| <2 years | 5,005 (15) | 54 (20) |
| 2–<10 years | 14,459 (43) | 113 (41) |
| ≥10 years | 9,216 (27) | 42 (15) |
| Hormone Therapy Use; N (%) | ||
| None | 23,442 (69) | 170 (62) |
| Estrogen Alone | 2,322 (6.9) | 32 (12) |
| Estrogen plus Progestin | 8,011 (24) | 71 (26) |
| ≥1 live birth; N (%) | 27,099 (80) | 212 (78) |
| Smoking Status; N (%) | ||
| Never | 19,289 (57) | 143 (52) |
| Former | 11,921 (35) | 122 (45) |
| Current | 2,639 (7.8) | 9 (3.2) |
| Alcohol Use; N (%) | ||
| Never or Former | 5,603 (17) | 49 (18) |
| Current, <1 drink/day | 23,296 (69) | 186 (68) |
| Current ≥1 drink/day | 4,903 (15) | 39 (14) |
| Ever Used Tamoxifen; N (%) | 526 (1.6) | 4 (1.5) |
Missing: Race (7 from cohort), education (6 from cohort), relative weight age 10 (98 from cohort, including 3 cases), BMI (11 from cohort), menopausal status (28 from cohort), hormone contraception (30 from cohort, including 1 case), hormone therapy (83 from cohort, including 1 case), parity (22 from cohort, including 1 case), smoking (9 from cohort), alcohol (56 from cohort), Tamoxifen (58 from cohort, including 1 case).
a
Excludes women who withdrew (N=2), were diagnosed with uterine cancer before baseline (N=366), had uncertain uterine cancer status (N=67), had a hysterectomy before baseline (N=15,602), or did not complete the personal care products questionnaire (n=989).